Medical Advisor II
Novo Nordisk is seeking a Medical Advisor II in Bengaluru to act as a scientific ambassador within their Medical Affairs and Medical Education department. The role involves leading medico-marketing activities, building KOL relationships, and driving clinical data dissemination in diabetes and cardio-metabolics. Candidates must possess an MD or MBBS with significant medical affairs experience. This position focuses on shaping scientific strategy and patient outcomes within a global healthcare leader.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
5+ years
Function
Healthcare Services
Work mode
Onsite, India
Company
Tier 2
What you will work on
Novo Nordisk is seeking a Medical Advisor II in Bengaluru to act as a scientific ambassador within their Medical Affairs and Medical Education department. The role involves leading medico-marketing activities, building KOL relationships, and driving clinical data dissemination in diabetes and cardio-metabolics. Candidates must possess an MD or MBBS with significant medical affairs experience. This position focuses on shaping scientific strategy and patient outcomes within a global healthcare leader.
TAL's take
High-caliber global pharmaceutical company with a clear medical-professional role scope.
The JD clearly defines the role responsibilities, required medical credentials, and the specific therapeutic focus.
Salaries at Novo Nordisk
19.3 LPA average
Based on 19 Grapevine salary entries for Novo Nordisk.
Other roles
0 - 2 years
4 LPA average
Range: 4 - 4 LPA
Product Management
2 - 4 years | 6
14 LPA average
Range: 14 - 14 LPA
Other roles
2 - 4 years | 6
17 LPA average
Range: 17 - 17 LPA
Operations
4 - 6 years | L5
10 LPA average
Range: 10 - 10 LPA
Must haves
- MD or MBBS degree
- Minimum 5 years experience in Medical Affairs or medico-marketing
- Expertise in diabetes and cardio-metabolic therapy areas
- Experience in medico-marketing and evidence generation
- Strong stakeholder management and relationship building with KOLs and HCPs
About the company
Global pharmaceutical company, though not a pure tech-native firm.
Posts mentioning Novo Nordisk
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market. - Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs. - Retail investors remain bullish on Amgen despite analyst disappointment. Source: [Asianet Newsable](https://newsable.asianetnews.com/markets/amgen-stock-sinks-on-modest-obesity-drug-results-but-retail-sentiment-remains-steady-snk9xh), [Asianet Newsable](https://newsable.asianetnews.com/markets/eli-lilly-novo-nordisk-shares-climb-premarket-as-biden-administration-mulls-medicare-medicaid-covering-for-obesity-drugs-retail-unmoved-snk72g)
The Controversial Rise of Weight Loss Drugs
- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)
The Looming Fiscal Crisis Over Revolutionary Weight Loss Drugs
- America faces a fiscal crisis over revolutionary weight loss drugs like Ozempic and Wegovy. - These drugs, produced by Novo Nordisk, have potential cardiovascular, mental health, and anti-cancer benefits. - However, their high cost in the U.S. compared to other countries could bankrupt Medicare. - If half of U.S. adults with obesity took these drugs, it would cost $411 billion annually. - The State Treasurer of North Carolina, Dale Folwell, is questioning the high cost and has asked the federal government to negotiate with Novo Nordisk to open up patents to generic manufacturers. Source: [More Perfect Union](https://youtu.be/JqHmvMjXuro)